Ocena postępowania diagnostycznego i terapeutycznego w ...

227. Kraakman-van der Zwet M, Overkamp W, Friedl A i wsp. Immortalization and
characterization of Nijmegen Breakage syndrome fibroblasts. Mutat Res. 1999; 434: 17-27.
228. Loeb D, Lederman H, Winkelstein J. Lymphoid malignancy as a presenting sign of ataxiateleangiectasia.
J Pediatr Hematol Oncol. 2000; 22: 464-46.
229. Laver JH, Kraveka JM, Hutchison RE i wsp. Advanced stage large-cell lymphoma in children
and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate
and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology
Group phase III trial. J Clin Oncol. 2005; 23: 541-47.
230. Salzburg J, Burkhard B, Zimmermann M i wsp. Prevalence, Clinical Pattern, and Outcome of
CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-
Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-Münster Group Report. J Clin Oncol.
2007; 25: 3915-22.
231. Łyskawa W. Chemioterapia w leczeniu choroby nowotworowej i jej neurotoksyczność.
Anestezjologia i Ratownictwo. 2009; 3: 80-87.
232. Amylon M, Shuster J, Pullen J i wsp. Intensive high-dose asparaginase consolidation improves
survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage
lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999; 13: 335-42.
233. Burkhardt B, Woessmann W, Zimmermann M i wsp. Impact of cranial radiotherapy on central
nervous system prophylaxis in children and adolescents with central nervous system-negative
stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006; 24: 491-99.
234. Sandlund JT, Pui CH, Zhou Y i wsp. Effective treatment of advanced-stage childhood
lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13
study. Leukemia. 2009; 23: 1127-30.
235. Marky I, Bjork O, Forestier E i wsp. Intensive chemotherapy without radiotherapy gives more
than 85% event-free survival for non-Hodgkin lymphoma without central nervous
involvement: a 6-year population based study from the Nordic society of pediatric hematology
and oncology. J Ped Hemato Oncol. 2004; 26; 555-60.
236. Antoccia A, Ricordy R, Maraschio P i wsp. Chromosomal sensitivity to clastogenic agents and
cell cycle perturbations in Nijmegen breakage syndrome lymphoblastoid cell lines. Int J
Radiat Biol. 1997; 71: 41-49.
237. Szmyd K. Czynniki ryzyka wystąpienia zakaŜenia krwi u dzieci z upośledzoną odpornością.
Adv Clin Exp Med. 2004; 13: 575–580.
238. Stefaniak J. Inwazyjna aspergilloza płuc u chorych z nowotworami układu krwiotwórczego:
etiologia, czynniki ryzyka, rozpoznawanie, leczenie. ZakaŜenia. 2008; 3: 14-20.
239. Wakulińska A, Dembowska –Bagińska B, Więckowska J i wsp. ZakaŜenia grzybicze w
trakcie leczenia choroby nowotworowej u dzieci. Nowa Pediatria 1998; 2: 42-44.
240. Böhme A., Ruhnke M., Buchheidt D. i wsp. Treatment of fungal infections in hematology and
oncology. Ann. Hematol. 2003; 82 supl. 2: 133–140.
241. Wrzesień-Kuś A. Profilaktyka i leczenie infekcji grzybiczych u chorych z neutropenią. Acta
Hematol Pol. 2001; 32: 15-28.
242. Sasse AD, Brandalise S, Clark OA, Richards S. Colony stimulating factors for prevention of
myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic
leukaemia. Cochrane Database Syst Rev. 2005;3:CD004139.
243. Ozkaynak MF, Krailo M, Chen Z i wsp: Randomized comparison of antibiotics with and
without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile
neutropenia: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2005; 45:
274-80.
244. Herbst C, Naumann F, Kruse EB i wsp. Prophylactic antibiotics or G-CSF for the prevention
of infections and improvement of survival in cancer patients undergoing chemotherapy.
Cochrane Database Syst Rev. 2009; 1: CD007107.
245. Relling MV, Boyett JM, Blanco JG i wsp: Granulocyte colony-stimulating factor and the risk
of secondary myeloid malignancy after etoposide treatment. Blood. 2003; 101: 3862-67.
246. Mühlemann K., Wenger C., Zenhäusern R. i wsp. Risk factors for invasive aspergillosis in
neutropenic patients with hematologic malignancies. Leukemia. 2005; 19: 545–50.
147